This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -211.67% and 75.31%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of 3.23% and 24.34%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of -82.61% and 14.35%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of -46.30% and 93.17%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Precision BioSciences (DTIL): Can Its 20.4% Jump Turn into More Strength?
by Zacks Equity Research
Precision BioSciences (DTIL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CHMP Endorses BioMarin's (BMRN) Voxzogo for Use in Infants
by Zacks Equity Research
A final decision study on BioMarin's (BMRN) Voxzogo to treat children above four months with achondroplasia is expected before year's end.
CHMP Endorses AstraZeneca's (AZN) Enhertu in Lung Cancer
by Zacks Equity Research
Data from a mid-stage study shows that treatment with AstraZeneca's (AZN) Enhertu achieved strong and durable tumor responses in certain non-small cell lung cancer patients.
After Plunging -27.45% in 4 Weeks, Here's Why the Trend Might Reverse for Precision BioSciences (DTIL)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Precision BioSciences (DTIL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Precision BioSciences (DTIL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Precision BioSciences (DTIL) delivered earnings and revenue surprises of 56.52% and 200.61%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Bristol Myers Squibb (BMY) Misses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Bristol Myers (BMY) delivered earnings and revenue surprises of -12.06% and 4.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -4.55% and 33.37%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Precision BioSciences (DTIL) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -8.33% and 78%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Insmed (INSM) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Insmed (INSM) delivered earnings and revenue surprises of -20% and 9.85%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Precision BioSciences (DTIL) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Precision BioSciences (DTIL) delivered earnings and revenue surprises of 37.14% and 37.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Kiniksa Pharmaceuticals, Ltd. (KNSA) Beats Q3 Earnings Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 76.32% and 12.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Eli Lilly (LLY) to Buy Hearing Loss Gene Therapy Maker Akouos
by Zacks Equity Research
Lilly (LLY) is set to acquire all the outstanding shares of Akouos for approximately $487 million plus a contingent value right for an aggregate amount up to approximately $610 million.
Kodiak Sciences (KOD) Q2 Earnings Beat, Eye Candidate in Focus
by Zacks Equity Research
Kodiak Sciences (KOD) reports narrower-than-expected loss for the second quarter of 2022. The focus is on the lead candidate, KSI-301, which is being developed for treating various retinal vascular diseases.
Axsome (AXSM) Q2 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Axsome (AXSM) reports narrower-than-expected loss for the second quarter of 2022. The company records its first sales of the sleep drug, Sunosi, which it acquired from Jazz.
Acadia's (ACAD) Q2 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Acadia (ACAD) reports a narrower-than-expected loss for the second quarter of 2022 while revenues surpass estimates. Tightens guidance for Nuplazid.
Global Blood (GBT) to be Acquired by Pfizer, Misses on Earnings
by Zacks Equity Research
Global Blood (GBT) is set to be acquired by Pfizer for around $5.4 billion. The company missed estimates for earnings while beating the same for revenues in the second quarter of 2022.
Precision BioSciences (DTIL) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2.33% and 23.80%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Deciphera (DCPH) Loss Narrows in Q2, Qinlock Drive Revenues
by Zacks Equity Research
Deciphera (DCPH) reports a narrower-than-expected loss in the second quarter of 2022 while revenues beat estimates. Shares rise.
Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q2
by Zacks Equity Research
Bayer (BAYRY) beats estimates for both earnings and revenues in the second quarter of 2022.
Editas' (EDIT) Loss Narrows in Q2, Revenues Trump Estimates
by Zacks Equity Research
Editas (EDIT) reports a narrower-than-expected loss in the second quarter of 2022 while its revenues beat estimates. Focus remains on the lead candidate, EDIT-101.
Novo Nordisk's (NVO) Q2 Earnings Miss, Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) missed estimates for earnings in the second quarter of 2022 while revenues beat the same, driven by growth in Diabetes and Obesity Care on higher GLP-1 revenues.